Nitric oxide, erectile dysfunction and beta-blocker treatment (MR NOED study): Benefit of nebivolol versus metoprolol in hypertensive men

Clinical and Experimental Pharmacology and Physiology

Volumn 34, Issue 4, 2007, Pages 327-331

  Brixius, K ^a   Middeke, M ^b   Lichtenthal, A ^c   Jahn, E ^c   Schwinger, R H G ^d  

^a GERMAN SPORT UNIVERSITY COLOGNE   (Germany)

^b Blutdruckinstitut   (Germany)

^c Berlin Chemie Menarini   (Germany)

^d Klinikum Weiden   (Germany)

Author keywords

Erectile function; Hypertension; Metoprolol; Nebivolol

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; METOPROLOL SUCCINATE; NEBIVOLOL; PLACEBO;

ADULT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ERECTILE DYSFUNCTION; ESSENTIAL HYPERTENSION; HETEROSEXUAL MALE; HUMAN; MALE; OUTPATIENT; PATIENT COMPLIANCE; PENIS ERECTION; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEXUAL BEHAVIOR; SEXUAL FUNCTION; SITTING; SYSTOLIC BLOOD PRESSURE;

ADULT; ANTIHYPERTENSIVE AGENTS; BENZOPYRANS; BLOOD PRESSURE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ETHANOLAMINES; HUMANS; HYPERTENSION; IMPOTENCE; MALE; METOPROLOL; MIDDLE AGED; NITRIC OXIDE; PATIENT COMPLIANCE; PENILE ERECTION; QUESTIONNAIRES; RECEPTORS, ADRENERGIC, BETA-1; TIME FACTORS; TREATMENT OUTCOME;

EID: 33846951170     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2007.04551.x     Document Type: Article

References (26)

1. NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA 1993; 270: 83-90.
2. Dusing R. Sexual dysfunction in male patients with hypertension: Influence of antihypertensive drugs. Drugs 2005; 65: 773-86.
3. Shabsigh R, Perelman MA, Lockhart DC, Lue TF, Broderick GA. Health issues of men: Prevalence and correlates of erectile dysfunction. J. Urol. 2005; 174: 662-7.
4. Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Worldwide prevalence of hypertension: A systematic review. J. Hypertens. 2004; 22: 11-19.
5. Fogari R, Zoppi A. Effects of antihypertensive therapy on sexual activity in hypertensive men. Curr. Hypertens. Rep. 2002; 4: 202-10.
6. Chobanian AV, Bakris GL, Black HR. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-52.
7. Weber MA. The role of the new beta-blockers in treating cardiovascular disease. Am. J. Hypertens. 2005; 18: S169-76.
8. Fogari R, Zoppi A. Sexual function in hypertensive males treated with lisinopril or atenolol: A cross-over study. Am. J. Hypertens. 1998; 11: 1244-7.
9. Fogari R, Zoppi A, Poletti L, Marasi G, Mugellini A, Corradi L. Sexual activity in hypertensive men treated with valsartan or carvedilol: A crossover study. Am. J. Hypertens. 2001; 14: 27-31.
10. Rosen RC, Cappelleri JC, Gendrano N. The international index of erectile function (IIEF): A state-of-the-science review. Int. J. Impot. Res. 2002; 14: 226-44.
11. Cheung BM, Ong KL, Man YB, Lam KS, Lau CP. Prevalence, awareness, treatment, and control of hypertension: United States National Health and Nutrition Examination Survey 2001-02. J. Clin. Hypertens. 2006; 8: 93-8.
12. Krousel-Wood M, Hyre A, Muntner P, Morisky D. Methods to improve medication adherence in patients with hypertension: Current status and future directions. Curr. Opin. Cardiol. 2005; 20: 296-300.
13. Cramer JA, Scheyer RD, Mattson RH. Compliance declines between clinic visits. Arch. Intern. Med. 1990; 150: 1509-10.
14. Waeber B, Burnier M, Brunner HR. Compliance with antihypertensive therapy. Clin. Exp. Hypertens. 1999; 21: 973-85.
15. Wespes E. Erectile dysfunction in the ageing man. Curr. Opin. Urol. 2000; 10: 625-8.
16. Ignarro LJ. Experimental evidences of nitric oxide-dependent vasodilatory activity of nebivolol, a third-generation beta-blocker. Blood Pressure 2004; 1: 2-16.
17. Dessy C, Saliez J, Ghisdal P et al. Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol. Circulation 2005; 112: 1198-205.
18. Brehm BR, Bertsch D, von Fallois J, Wolf SC. Beta-blockers of the third generation inhibit endothelin-1 liberation, mRNA production and proliferation of human coronary smooth muscle and endothelial cells. J. Cardiovasc. Pharmacol. 2000; 36 (Suppl. 1): S401-3.
19. Garban HJ, Buga GM, Ignarro LJ. Estrogen receptor-mediated vascular responsiveness to nebivolol: A novel endothelium-related mechanism of therapeutic vasorelaxation. J. Cardiovasc. Pharmacol. 2004; 43: 638-44.
20. Lekakis JP, Protogerou A, Papamichael C et al. Effect of nebivolol and atenolol on brachial artery flow-mediated vasodilation in patients with coronary artery disease. Cardiovasc. Drugs Ther. 2005; 19: 277-81.
21. Kamp O, Sieswerda GT, Visser CA. Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension. Am. J. Cardiol. 2003; 92: 344-8.
22. Nodari S, Metra M, Dei Cas L. Beta-blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs. Nebivolol. Eur. J. Heart Fail. 2003; 5: 621-7.
23. Andersson KE, Wagner G. Physiology of penile erection. Physiol. Rev. 1995; 75: 191-236.
24. Moore RA, Derry S, McQuay HJ. Indirect comparison of interventions using published randomised trials: Systematic review of PDE-5 inhibitors for erectile dysfunction. BMC Urol. 2005; 5: 18-34.
25. Bloch W, Mehlhorn U, Krahwinkel A. Evidence for the involvement of endothelial nitric oxide synthase from smooth muscle cells in the erectile function of the human corpus cavernosum. Urol. Res. 1998; 26: 129-35.
26. Cirino G, Sorrentino R, di Villa Bianca R et al. Involvement of beta 3-adrenergic receptor activation via cyclic GMP- but not NO-dependent mechanisms in human corpus cavernosum function. Proc. Natl Acad. Sci. USA 2003; 100: 5531-6.